Transfusion Medicine and Hemotherapy最新文献_第9页

55. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e. V. (DGTI), 21.–23. September 2022, Mannheim, ABSTRACTS 55. 德国输血和免疫血液学协会年会2022年9月曼海姆文摘

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-09-01 DOI: 10.1159/000525886

J. Hagele, M. Proffen, J. Scholz, C. Ludwig, C. Vieweg, A. Grempels, D. Fabricius, R. Lotfi, S. Korper, G. Adler, H. Schrezenmeier, B. Jahrsdorfer

引用次数: 32

Hämophilie A-Therapie mit Emicizumab in der klinischen Praxis 借血友病a疗法进行临床治疗

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-09-01 DOI: 10.1159/000527163

引用次数: 0

Front & Back Matter 正面和背面事项

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-08-01 DOI: 10.1159/000526342

引用次数: 0

Front & Back Matter 正面和背面

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-06-01 DOI: 10.1159/000525363

引用次数: 0

Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis 新冠肺炎患者血液衍生物治疗的有效性和安全性：系统评价和Meta-Analysis

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-04-25 DOI: 10.1159/000524125

Z. Fei, Zhongsheng Chen, Xi Du, Haijun Cao, Changqing Li

{"title":"Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis","authors":"Z. Fei, Zhongsheng Chen, Xi Du, Haijun Cao, Changqing Li","doi":"10.1159/000524125","DOIUrl":"https://doi.org/10.1159/000524125","url":null,"abstract":"Background: The outbreak of COVID-19 has resulted in more than 200 million infections and 4 million deaths. The blood derivative therapy represented by intravenous immunoglobulin (IVIG) and convalescent plasma (CP) therapy may be the promising therapeutics for COVID-19. Methods: A systematic article search was performed for eligible studies published up to August 3, 2021, through the PubMed, Embase, Cochrane Library. The included articles were screened by using rigorous inclusion and exclusion criteria. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated. Results: A total of 5 IVIG therapy and 13 CP therapy randomized controlled trials were included with a sample size of 13,696 subjects diagnosed with COVID-19. IVIG could reduce the mortality compared with the control group (RR 0.65, 95% CI: 0.46–0.93, p = 0.02). The use of CP did not effectively reduce the mortality (RR 0.97, 95% CI: 0.91–1.03, p = 0.38), the length of hospital stay (MD −0.47, 95% CI: −4.13 to 3.20, p = 0.80), and the mechanical ventilation use (RR = 0.98, 95% CI: 0.89–1.07, p = 0.62) of the patients with COVID-19. Treatment with IVIG or CP was not significantly associated with an increase in reported adverse events (RR 1.07, 95% CI: 0.94–1.22, p = 0.28). Conclusions: Treatment with IVIG could be effective and safe to improve survival for patients with COVID-19. But the benefit of CP in the treatment of COVID-19 is limited. The certainty of the evidence was moderate for all outcomes.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"49 1","pages":"388 - 400"},"PeriodicalIF":2.2,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41738203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Safety of Plasmapheresis in Donors with Low IgG Levels: Results of a Prospective, Controlled Multicentre Study. 血浆置换在低IgG水平供者中的安全性:一项前瞻性、对照多中心研究的结果。

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-04-14 eCollection Date: 2022-09-01 DOI: 10.1159/000522528

Rainer Moog, Teija Laitinen, Uwe Taborski

{"title":"Safety of Plasmapheresis in Donors with Low IgG Levels: Results of a Prospective, Controlled Multicentre Study.","authors":"Rainer Moog, Teija Laitinen, Uwe Taborski","doi":"10.1159/000522528","DOIUrl":"https://doi.org/10.1159/000522528","url":null,"abstract":"Background and objectives: Although plasmapheresis is generally considered safe, there are still concerns about the long-term effects of plasma donation on immunoglobulin G (IgG) levels. The aim of the present study was to investigate if there is a need to permanently defer donors who donated three times with an IgG level below 6.0 g/L.Study design and methods: From September 2007 to December 2017, adverse events (AEs) including infections were analysed from data of a prospective, controlled multicentre study of healthy volunteer donors, participating in an individualized plasmapheresis programme stratified by initial IgG level and body weight (individualized arm) or in standard plasmapheresis according to national guidelines (control arm). IgG was monitored at every fifth donation, and donors with IgG levels below the threshold were identified and followed up for possible AEs.Results: In total, 97,540 donations in 1,462 donors in the control arm and 1,491,223 donations in 14,281 donors in the individualized arm were included. Donation-based incidences of at least severe AEs and any infections were 0.019% and 0.192% in the control arm, and 0.014% and 0.153% in the individualized arm. Three or more IgG-measurements below the threshold occurred in 38.2% of control arm donors and 20.9% of individualized arm donors. There were no increased incidence rates of at least severe AEs or any infections in donors with ≥3 IgG-measurements below the threshold in either donor's arm.Conclusions: Our data show no signs of compromised donor safety in donors with ≥3 IgG-measurements below the threshold, indicating that plasmapheresis is feasible and safe in these donors.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"49 5","pages":"271-279"},"PeriodicalIF":2.2,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

PharmaNews PharmaNews

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-04-01 DOI: 10.1159/000524259

引用次数: 0

Front & Back Matter 正面和背面事项

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-04-01 DOI: 10.1159/000524440

Gregor Bein

引用次数: 0

Front & Back Matter 正面和背面

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-02-01 DOI: 10.1159/000522356

Gregor Bein

引用次数: 0

PharmaNews PharmaNews

IF 2.2 4区医学

Transfusion Medicine and Hemotherapy Pub Date : 2022-02-01 DOI: 10.1159/000522076

{"title":"PharmaNews","authors":"","doi":"10.1159/000522076","DOIUrl":"https://doi.org/10.1159/000522076","url":null,"abstract":"Die aktualisierte Fachinformation für den oralen Januskinase (JAK)-Inhibitor Ruxolitinib (Jakavi®) enthält detailliertere Dosierungsempfehlungen zur Behandlung von krankheitsbedingter Splenomegalie oder Symptomen bei Erwachsenen mit primärer Myelofibrose, Post-Polycythaemia-vera-Myelofibrose oder Post-essenzieller-Thrombozythämie-Myelofibrose. Diese beinhalten detailliertere Angaben zur Anfangsdosis des oralen JAK-Inhibitors in Abhängigkeit von der Thrombozytenzahl sowie zur Dosisanpassung bei Thrombozytopenie unter laufender Behandlung. Thrombozytopenien (Thrombozytenzahl < 150 000/μl im Blut) können bei der Myelofibrose als Folge der erkrankungsbedingten Splenomegalie, aber auch als Nebenwirkung der Therapie auftreten [1, 2]. Die Aktualisierung der Fachinformation basiert auf den Ergebnissen der PhaseIb-Studie EXPAND, die die Dosierung von Ruxolitinib bei Thrombozytenzahlen von 50 000–100 000 untersuchte [3, 4]. Die nun empfohlene Anfangsdosis von Ruxolitinib liegt zwischen 5 und 20 mg 2-mal täglich (bid) und richtet sich nach der Thrombozytenzahl bei Behandlungsbeginn [1].* Tritt später im Behandlungsverlauf eine Thrombozytopenie auf, soll die Dosis in Abhängigkeit von der Thrombozytenzahl und der Dosis zum Zeitpunkt des Thrombozytenabfalls differenziert angepasst werden [1]. Bei Thrombozytenzahlen < 50 × 109/l muss die Therapie pausiert werden – unabhängig von der Ausgangsdosis [1].","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"49 1","pages":"65 - 66"},"PeriodicalIF":2.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45177553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0